Current use and safety of novel oral anticoagulants in adults with congenital heart disease

results of a nationwide analysis including more than 44 000 patients

  • Freisinger, Eva
  • Gerß, Joachim
  • Makowski, Lena
  • Marschall, Ursula
  • Reinecke, Holger
  • Baumgartner, Helmut
  • Koeppe, Jeanette
  • Diller, Gerhard-Paul

  • Department of Cardiology I—Coronary and Peripheral Vascular Disease, Heart Failure, University Hospital Muenster, Albert Schweitzer Campus 1, A1, 48149 Muenster, Germany

    Institute of Biostatistics and Clinical Research, University of Muenster, Schmeddingstrasse 56, 48149 Muenster, Germany

    Department of Medicine and Health Services Research, BARMER Health Insurance, Lichtscheider Strasse 89, 42285 Wuppertal, Germany

    Department of Cardiology III—Adult Congenital and Valvular Heart Disease, University Hospital Muenster, Albert Schweitzer Campus 1, A1, 48149 Muenster, Germany

    Competence Network for Congenital Heart Defects, Augustenburger Pl. 1, 13353 Berlin, Germany

Jeanette Koeppe and Gerhard-Paul Diller contributed equally to this work.

Corresponding author. Tel: +49 251 83 46138, Fax: +49 251 83 46109, Email: [email protected]

Received May 22, 2020

Received in revised form August 19, 2020

Accepted September 25, 2020

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

European Heart Journal 41(43):p 4168-4177, November 14, 2020. | DOI: 10.1093/eurheartj/ehaa844

Corresponding Article

Non-vitamin K oral anticoagulants in adults with congenital heart disease

quod non?

  • Verhamme, Peter
  • Budts, Werner
  • Van de Werf, Frans
European Heart Journal 41(43):p 4178-4180, November 14, 2020. | DOI: 10.1093/eurheartj/ehaa867
Copyright © Copyright Oxford University Press 2020.